Form 4: Moderna Chief Legal Officer Shannon Klinger Awarded 188,761 Restricted Stock Units

Moderna's Chief Legal Officer, Shannon Klinger, received 188,761 restricted stock units that will vest over time.

Summary

• Shannon Klinger, the Chief Legal Officer of Moderna, Inc., was granted 188,761 restricted stock units on December 5, 2024.
• These restricted stock units will convert to common stock as they vest.
• 25% of the shares will vest on December 5, 2025, and the remaining shares will vest in twelve equal quarterly installments thereafter.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management interests with shareholders. There is no indication of any negative sentiment.

Positives

• The grant of restricted stock units aligns the Chief Legal Officer's interests with the long-term performance of the company.
• The vesting schedule encourages continued service and contribution to Moderna.

Future Outlook

The restricted stock units will vest over time, incentivizing the Chief Legal Officer to remain with the company and contribute to its success.

Industry Context

The granting of restricted stock units is a common practice in the biotechnology industry to attract and retain key executives.

Comparison to Industry Standards

• Many biotechnology companies use restricted stock units as part of their executive compensation packages.
• The vesting schedule of 25% after one year and the remainder over three years is a fairly standard practice.
• Companies like BioNTech and Novavax also use similar equity-based compensation strategies for their executives.

Stakeholder Impact

• Shareholders may view this as a positive sign of aligning management interests with company performance.
• Employees may see this as a standard practice for executive compensation.

Key Dates

Keywords

Moderna, Restricted Stock Units, Stock Options, Executive Compensation, Shannon Klinger, Chief Legal Officer, Vesting